Florida Clinical Trials Report — May 2026

For Floridians considering participation in clinical research, May 2026 presents a critical window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 322 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 70 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, metabolic disorders, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Healthy volunteers (7 trials)
• Advanced solid tumor (6 trials)
• Amyotrophic lateral sclerosis (6 trials)
• Breast cancer (6 trials)
• Obesity (5 trials)
• Cancer (4 trials)
• Traumatic brain injury (4 trials)
• Type 2 diabetes (4 trials)
• Ovarian cancer (4 trials)
• Overweight (4 trials)

Major Research Initiatives Launch Across Florida

This month brings several high-profile new trials to Florida, including significant Phase 2 and 3 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to infectious diseases and chronic conditions.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Pfizer is leading NCT07573462, a Phase 3 study named "A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants." This trial will involve 2,400 healthy infants and aims to learn about the safety and immune response of a new pneumococcal vaccine compared to an existing one. This study includes children as participants.
• Novo Nordisk A/S is also sponsoring two related Phase 3 studies focused on obstructive sleep apnoea: NCT07571005 and NCT07571109. Both studies investigate the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea, with NCT07571005 focusing on those not treated with positive airway pressure and NCT07571109 on those who are. Each trial plans to enroll 300 participants.
• The Florida Institute for Human and Machine Cognition is sponsoring NCT07572266, "Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults." This study aims to enroll 226 participants to investigate how exercise can mitigate aging-related functional declines. This trial includes older adults.
• Adia Med of Winter Park LLC is sponsoring NCT07572890, a Phase 2 study titled "Adia Med of Winter Park LLC Chronic Kidney Disease Research Study." This trial aims to enroll 100 participants to evaluate the safety and potential kidney function improvement of a new regenerative treatment using umbilical cord blood-derived stem cells and exosomes combined with glutathione in adults with chronic kidney disease.

Florida's Evolving Research Landscape: New Studies and Geographic Spread

This month, Florida saw the opening of 21 new clinical trials, a notable decrease compared to the 76 trials that launched in March 2026. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 3,823 clinical trials currently recruiting across 196 cities and 4,600 research sites.

The majority of new research initiatives this month are concentrated in Florida's major metropolitan areas. Top cities for new trial launches include:

• Miami (6 trials)
• Jacksonville (3 trials)
• Coral Gables (3 trials)
• Winter Park (2 trials)
• Tampa (2 trials)
• Daytona Beach (2 trials)
• Pembroke Pines (2 trials)
• Naples (2 trials)
• Clearwater (2 trials)
• Gainesville (2 trials)

This distribution indicates that while major cities remain hubs for new research, opportunities are also emerging in diverse locations across the state, enhancing accessibility for a wider range of participants.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Obesity (4 trials)
• Overweight (2 trials)
• Obstructive sleep apnoea (2 trials)
• Type 2 diabetes (2 trials)
• Aphasia (1 trial)
• Apraxia of speech (1 trial)
• Autism (1 trial)
• Brain metastases (1 trial)
• Chin augmentation (1 trial)
• Chronic kidney disease (1 trial)

The types of interventions being studied are varied, with drug trials leading the way, accounting for 8 of the new trials. Other new studies include biological treatments, medical devices, behavioral interventions, and dietary supplements.

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 21 new trials launched this month, 16 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials are open to children, offering opportunities for younger participants to engage in research that could benefit their age group. 2 new trials are female-only, and 1 is male-only, addressing specific health needs for these demographics.

For individuals without a specific medical condition, there are significant opportunities to contribute. 9 of the new trials this month are actively seeking healthy volunteers. Across Florida, a total of 450 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions continue to play a vital role in Florida's research ecosystem, with the University of Florida sponsoring 3 of the new trials. Industry sponsors, including Novo Nordisk A/S (4 new trials) and Eli Lilly and Company (1 new trial), are also driving significant research efforts. Overall, industry sponsors account for 12 of the new studies this month, while academic and other sponsors account for 9.

As we move through May, the focus will likely shift towards the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Florida.